Can the EU establish common rules to limit sperm and egg donation?
Regulation of sperm and egg donation falls entirely under the jurisdiction of each individual country. And the legislation varies from one to another.
The maximum number of children that can be conceived from a single donor varies from one in Cyprus to 15 in Germany. And some member states prefer to limit the number of families that can use the same donor. Sweden and Belgium cap it at six families, while Denmark allows up to 12.
For their part, commercial sperm banks set their own limits, which has resulted in some donors fathering up to 75 children.
A recent high-profile case involved a Danish donor who unknowingly carried a rare genetic mutation that increases the risk of cancer and who helped conceive at least 67 children in Europe, 10 of whom were diagnosed with cancer.
These "super donors" increase the risk of unintentional incest and the spread of genetic abnormalities. Additionally, there's the issue of donor anonymity.
'Sperm donation is anonymous in Italy, but not in the Netherlands. And in some countries, like Austria, it is semi-anonymous, which means that sperm donation is only anonymous between the donor and the recipients," said Amandine Hess, who has covered this topic for Euronews. "Due to DNA testing and social media, donor anonymity can no longer be guaranteed 100%, so it's increasingly common for children to connect with their half-siblings or donor, which can be challenging for them and also for their families,' she added.
A European Donor Registry
Because of these ethical concerns, eight EU health ministers—Belgium, Finland, France, Hungary, Netherlands, Romania, Spain, Sweden—joined forces to propose the establishment of common regulations on sperm donation in Europe.
The proposal includes the possibility of creating a European donor registry, as regulatory differences lead patients and donors to travel to countries with more lenient rules. Spain, for example, carries out 50% of egg donation treatments and even receives patients from Latin America.
"I believe it is more than necessary to create a European registry," said MEP Elena Nevado del Campo, and vice-chair of the public health committee. 'Many national laws already provide for the creation of such registries, but in reality, many have not been implemented, and more needs to be done for ethical reasons. International registries should be established, since these donations also cross borders beyond the European Union itself,' she told Euronews.
According to the Oviedo Convention, an international treaty from the Council of Europe that sets ethical principles for biomedicine, the human body and its parts must not give rise to financial gain.
But commercial cryopreservation banks make profits through the handling, freezing, and storage of sperm and eggs, as well as through the screening of potential donors.
This cross-border business will likely continue to grow, along with the ethical and public health issues it raises.
Watch the video here!
Journalist: Mared Gwyn Jones
Content production: Pilar Montero López
Video production: Zacharia Vigneron
Graphism: Loredana Dumitru
Editorial coordination: Ana Lázaro Bosch and Jeremy Fleming-Jones
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
3 hours ago
- Euronews
Brussels targets tobacco products with a new set of eurotaxes
On Wednesday, the European Commission unveiled two major proposals: a long-awaited revision of the Tobacco Taxation Directive and a brand new measure known as the Tobacco Excise Duty Own Resource (TEDOR). The revision of the Tobacco Taxation Directive aims to raise minimum excise duty rates—taxes levied on specific goods, such as tobacco, typically at the point of production or import. Under the new rules, the scope of the directive would also be broadened to include e-cigarette liquids, chewing and nasal tobacco, nicotine pouches, other nicotine products, and raw tobacco. The TEDOR proposal, presented separately as part of the EU's new €2 trillion long-term budget framework, would introduce a fresh stream of EU revenue independent of contributions from member states. Under TEDOR, a uniform 15% call rate would apply to the quantities of manufactured tobacco and related products released for consumption, based on the minimum excise rate applicable in each country. The Commission expects TEDOR to generate approximately €11.2 billion annually. However, it remains unclear whether the revenue will be used to repay borrowing under the NextGenerationEU fund or to reduce national contributions to the EU budget for new priorities. 'Own resources have no specific dedication. They always enter the yearly budget without being earmarked,' an EU official said. The official added that the revised tobacco taxation directive is "complementary but independent" from the TEDOR proposal. First major tobacco legislative tweaks in years These two proposals mark the first significant EU tobacco taxation legislation in years. A broader update of EU tobacco rules—once anticipated during Commission President Ursula von der Leyen's previous term—has been delayed and is currently on hold. The "Europe's Beating Cancer Plan", a flagship health initiative of the von der Leyen Commission, underscored the importance of taxation in reducing tobacco use, particularly among young people. However, repeated delays have raised questions about the influence of the tobacco industry on policymaking. The revised Tobacco Excise Directive will adjust minimum excise duties for traditional tobacco products, which currently date back to 2010. Under EU law, member states must impose a minimum rate on cigarette excise duties, though they are allowed to exceed that rate based on national priorities. With the new revised rules, the Commission wants to set excise duty on cigarettes at no less than 7.5% and no more than 76.5% of the total tax burden. The revision also aims to tighten controls on raw tobacco, which is often diverted into illicit markets. Cross-border shopping—when tobacco is bought in one country but consumed in another—would now be better tracked and accounted for. The EU plans to expand the current electronic system used to monitor excise goods movement to also include raw tobacco under its monitoring. Next steps: challenging path ahead Both the revised Tobacco Taxation Directive and TEDOR face significant political hurdles. In the EU, tax legislation can only be adopted by unanimous agreement in the Council of the European Union, where all member states are represented. The European Parliament is consulted but does not have legislative power in this area. Countries such as Italy and Greece have already voiced opposition to any tax-driven price increases on tobacco products. However, momentum may be building: in March 2025, health ministers from 12 member states sent a letter to EU health Commissioner Olivér Várhelyi urging more decisive action on tobacco and novel nicotine products. Despite growing support, reaching unanimity remains a major challenge, especially for revenue-generating measures like TEDOR, which also require approval by all member states in line with their national constitutional procedures.
Euronews
8 hours ago
- Euronews
Why some countries' healthcare spending is more wasteful than others
Wealthy countries spend trillions of euros on health care every year, but not all of them are getting their money's worth, a new analysis has found. Higher levels of health spending are linked to better outcomes, but after a certain point, more money may not be efficient or practical. The more a country spends on medical care, the more it must pay to continue boosting citizens' health, according to the study published in The Lancet Global Health journal. In countries that spend $100 (€85) per capita on health care, for example, spending another $92 (€79) per person earns them an additional year of healthy life. But in countries that spend $5,000 (€4,272) per capita, another healthy year would cost $11,213 (€9,580). 'Countries around the world have made significant progress in converting dollars into health,' wrote the researchers from the US-based Institute for Health Metrics and Evaluation (IHME). 'However, more reductions in inefficiency need to be made in an era of tightening health-care budgets [and] to maximise the returns on their health care spending'. The researchers determined health spending inefficiency by comparing a country's total health spending – including the amount they spend and how they spend it – to the number of years people there can expect to live in good health. The study included 201 countries and territories, and covered a 28-year period from 1995 to 2022. Drivers of efficient and wasteful spending Globally, health spending became more efficient between 1995 and 2019, but this progress was disrupted during the COVID-19 pandemic. While it began to recover in 2022, there are still major 'inefficiency gaps' between countries, the analysis found. The United States spends more per capita on healthcare than any other wealthy country. But its system is not particularly efficient, which costs Americans 6.2 years of healthy life. China was the most efficient country with zero waste, meaning it optimised its spending to deliver the best possible health outcomes for its citizens, according to the analysis. Most European countries were considered fairly efficient. Exceptions included Ukraine, Lithuania, Latvia, and to a lesser extent, the Netherlands, Belgium, Belarus, Finland, Norway, and the United Kingdom. Beyond their actual budgets, the most efficient countries tended to have better governance, greater uptake of primary care, infrastructure that makes it possible for people to access medical services, and more public spending on health care compared with the private sector. Notably, the study does not take into account health care quality, but rather tracks how well a country scores among those with similar levels of spending. The study authors said policymakers could use the findings to maximise their investments in health, which could be particularly important given many countries are facing pressure on their budgets. 'Expanding government-provided health-care coverage would decrease the inefficiency of the health care system,' the researchers argued. 'Countries should also focus on strengthening democracy, building infrastructure, and increasing the use of, and access to, preventive care,' they added.
Euronews
a day ago
- Euronews
Trump officials are pushing psychedelic therapy. Will it help or hurt?
For decades, proponents of psychedelic drugs have pushed a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for patients grappling with depression, trauma and other hard-to-treat conditions. In the United States, a presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' US health secretary Robert F Kennedy Jr recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. The Trump administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants, and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organisation has pursed the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved'". US regulators may reconsider MDMA Under former US President Joe Biden, the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD), citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first US approval of a psychedelic for medical use, and European researchers said it likely set the field back there as well. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new programme promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. Links to psychedelic advocates US health agencies also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardise patients. "If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.' Nora Volkow, the longtime director of the US National Institute on Drug Abuse, said her agency remains interested in psychedelics. It is funding a US drugmaker that's working to develop a safer, synthetic version of ibogaine, which is a potent psychedelic made from a shrub that's native to West Africa. Texas recently launched a $50 million (€42.7 million) trial to test ibogaine as a treatment for opioid addiction, PTSD, and other conditions. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them".
